Wednesday, July 8, 2026

biotech · Uveal Melanoma · Choroidal Melanoma · AURA

Aura Biosciences

Aura Biosciences clinical programs — 3 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Boston, USA HQ
2009 Founded
128 Employees
Public company Type
AURA · NYSE Ticker
Company details
Status
Public
HQ
Boston, USA
Founded
2009
Employees
128
Programs
6
Drugs
3
Patents
17
Intelligence · Clinical Programs

Aura Biosciences projects

3 ClinicalTrials.gov programs sponsored by Aura Biosciences.

Aura Biosciences has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AU-011

    Aura Biosciences

    Eye Cancer

    phase 2 small molecule active

    1 trial
  2. AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial
  3. Light-activated AU-011

    Aura Biosciences

    Uveal Melanoma

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Aura Biosciences have?

3 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.